Rainbow Childrens Medicare Analyst Review May 2026

This Rainbow Childrens Medicare analyst review for May 2026 covers the key data investors need for RAINBOW at its current price of Rs 1,339.00. Rainbow Childrens Medicare (NSE: RAINBOW) is India’s largest paediatric hospital chain with a market capitalisation of approximately Rs 8,500 crore, operating 15 hospitals focused on children and women’s health. The analyst consensus target of Rs 1,800 implies meaningful upside, and this Rainbow Childrens Medicare analyst review examines technical levels, business segments, valuation, and key risks for RAINBOW through FY27.

Click Here – Get Free Investment Predictions

Rainbow Childrens Medicare Company Snapshot May 2026

Rainbow’s paediatric specialisation in neonatal intensive care, paediatric cardiac surgery, and paediatric oncology creates a distinct clinical moat. The company is expanding into Tier 2 cities and adding fertility and obstetrics. The table below summarises the key data referenced in this Rainbow Childrens Medicare analyst review.

Parameter	Value
NSE Ticker	RAINBOW
Sector	Healthcare – Paediatric Hospitals
CMP (May 2026)	Rs 1,339.00
52 Week High	Rs 1,645.70
52 Week Low	Rs 1,084.00
Market Cap	Rs 8,500 Crore
Trailing P/E	55x
Analyst Consensus Target	Rs 1,800
Bull Case Target	Rs 2,200
Bear Case Target	Rs 1,300

Analyst Insight in This Rainbow Childrens Medicare Analyst Review

Senior Research Analyst Ankit Jaiswal flags Rainbow Childrens Medicare as a stock to watch in May 2026. At Rs 1,339.00, Ankit Jaiswal identifies key support in the Rs 1106 to Rs 1272 band and resistance near Rs 1419. He suggests watching Rainbow Childrens Medicare for a potential move toward Rs 1,800, subject to Healthcare – Paediatric Hospitals sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Rainbow Childrens Medicare analyst review and does not constitute a trade recommendation.

Technical Analysis in This Rainbow Childrens Medicare Analyst Review

At Rs 1,339.00, RAINBOW is trading within its 52-week band of Rs 1,084.00 to Rs 1,645.70. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 1106 to Rs 1272 band while resistance is seen in the Rs 1419 to Rs 1570 zone. A sustained move above Rs 1419 could open the path toward the analyst consensus target of Rs 1,800 as outlined in this Rainbow Childrens Medicare analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 1106 to Rs 1272 – investors tracking this Rainbow Childrens Medicare analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for RAINBOW.
• Resistance Zone: Rs 1419 to Rs 1570 – a sustained close above Rs 1419 would be a positive breakout signal worth flagging in this Rainbow Childrens Medicare analyst review.
• Medium-Term Target: The analyst consensus of Rs 1,800 represents the base-case upside scenario in this Rainbow Childrens Medicare analyst review.

Business Segment Analysis

Paediatric Hospitals (NICU, Cardiac Surgery)

This is the primary revenue and margin driver for Rainbow Childrens Medicare, directly supporting the earnings trajectory toward the consensus target of Rs 1,800.

Women and Mother-Child Health Services

This segment adds scale and diversification to Rainbow Childrens Medicare’s business model and is a meaningful EPS contributor through FY27 and FY28.

Fertility and Reproductive Medicine

This represents the medium-term growth frontier for Rainbow Childrens Medicare and a key re-rating catalyst over the next 12 to 24 months.

Valuation in This Rainbow Childrens Medicare Analyst Review

At Rs 1,339.00, Rainbow Childrens Medicare trades at a trailing P/E of 55x. This Rainbow Childrens Medicare analyst review presents three scenarios: a bull case of Rs 2,200 on strong earnings delivery and sector tailwinds, a base case of Rs 1,800 at analyst consensus, and a bear case of Rs 1,300 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Rainbow Childrens Medicare analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 2,200	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 1,800	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,300	Earnings miss or macro headwinds

Trade Outlook for Rainbow Childrens Medicare

Based on the technical and fundamental analysis in this Rainbow Childrens Medicare analyst review, investors might watch RAINBOW near the support zone of Rs 1106 to Rs 1272 for potential opportunities. A flag above Rs 1419 could suggest improving momentum toward Rs 1,800. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Rainbow Childrens Medicare in FY27

A well-rounded Rainbow Childrens Medicare analyst review must assess downside risks. Key risks for Rainbow Childrens Medicare include a macro slowdown affecting Healthcare – Paediatric Hospitals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in RAINBOW.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Rainbow Childrens Medicare Analyst Review Verdict for 2026

This Rainbow Childrens Medicare analyst review concludes that at Rs 1,339.00, RAINBOW offers a defined risk-reward with a consensus target of Rs 1,800. The 52-week range of Rs 1,084.00 to Rs 1,645.70 provides context on the current entry point. Use this Rainbow Childrens Medicare analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on RAINBOW.

Frequently Asked Questions: Rainbow Childrens Medicare Analyst Review 2026

What is the analyst target for Rainbow Childrens Medicare in 2026?

The analyst consensus target is Rs 1,800, with a bull case of Rs 2,200 and a bear case of Rs 1,300. This Rainbow Childrens Medicare analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Rainbow Childrens Medicare a good investment at Rs 1,339.00?

At Rs 1,339.00 with a P/E of 55x and a consensus target of Rs 1,800, this Rainbow Childrens Medicare analyst review is constructive for medium to long-term investors in the Healthcare – Paediatric Hospitals sector. Always consult a SEBI-registered advisor before investing.

What is Rainbow Childrens Medicare’s 52-week high and low?

The 52-week high is Rs 1,645.70 and the 52-week low is Rs 1,084.00. At Rs 1,339.00, RAINBOW is positioned within this range as detailed in this Rainbow Childrens Medicare analyst review.

What are the key risks for Rainbow Childrens Medicare?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Healthcare – Paediatric Hospitals sector, all assessed in this Rainbow Childrens Medicare analyst review.

Where can I track live data for Rainbow Childrens Medicare?

Track Rainbow Childrens Medicare’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Rainbow Childrens Medicare analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.